Yifan (Ningxia) granted prothioconazole technical registration in China

On October 10, 2022, the prothioconazole technical of Yifan (Ningxia) Co., Ltd., a wholly owned subsidiary of Yifan Biotechnology Group, was granted registration by China’s ICAMA, with the registration certificate number, PD20220242, which is valid until October 8, 2027. 

Yifan Group has been dedicated to the global market development of prothioconazole. In the European Union (EU) market, technical equivalence was approved at a much earlier date for the product of Yifan (Ningxia), while in the Brazilian market, the registration of prothioconazole sourced from Yifan (Ningxia) is currently being evaluated, which is expected to be approved in 2023.

Going forward, Yifan Group will continue establishing prothioconazole as its strategic core product for promotion in the global market. It is reported that the company is planning to begin registrations in the North America, South America and Asia-Pacific markets in the near future, which will facilitate worldwide customers’ development of formulations based on its prothioconazole technical.

Click to Subscribe: China Special Bi-weekly Newsletter